Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Tycel Phillips

Tycel Phillips

MD
City of Hope
An update from ASH 2023: advancements in NHL treatment 0:51
An update from ASH 2023: advancements in NHL treatment
Tycel Phillips • 10 Dec 2023
A retrospective analysis of real-world data from patients treated for R/R follicular lymphoma 1:54
A retrospective analysis of real-world data from patients treated for R/R follicular lymphoma
Tycel Phillips • 10 Dec 2023
Optimal sequencing of CAR-T and bispecifics in NHL 1:55
Optimal sequencing of CAR-T and bispecifics in NHL
Tycel Phillips • 10 Dec 2023
GLOBRYTE: investigating glofitamab monotherapy in patients with R/R MCL 1:17
GLOBRYTE: investigating glofitamab monotherapy in patients with R/R MCL
Tycel Phillips • 10 Dec 2023
Ongoing clinical trials to look out for in lymphoma 1:43
Ongoing clinical trials to look out for in lymphoma
Tycel Phillips • 7 Sep 2023
The need to improve prognostic tools and implement targeted therapies in follicular lymphoma 2:27
The need to improve prognostic tools and implement targeted therapies in follicular lymphoma
Tycel Phillips • 7 Sep 2023
Overcoming CAR-T cell resistance in MCL: armored CARs, dual-targeting approaches & combinations 1:36
Overcoming CAR-T cell resistance in MCL: armored CARs, dual-targeting approaches & combinations
Tycel Phillips • 7 Sep 2023
Updates on the use of bispecific antibodies in MCL & the need for more studies in this space 1:43
Updates on the use of bispecific antibodies in MCL & the need for more studies in this space
Tycel Phillips • 7 Sep 2023
Updates on the use of CAR-T therapy in MCL 1:50
Updates on the use of CAR-T therapy in MCL
Tycel Phillips • 7 Sep 2023
Lymphoma CAR and bispecific updates
Loretta Nastoupil et al. • 12 May 2023
Acalabrutinib in combination with bendamustine & rituximab in treatment-naïve or R/R MCL 1:31
Acalabrutinib in combination with bendamustine & rituximab in treatment-naïve or R/R MCL
Tycel Phillips • 4 Jun 2023
Estimating long-term outcomes in patients with cHL using an oncology simulation model 1:18
Estimating long-term outcomes in patients with cHL using an oncology simulation model
Tycel Phillips • 4 Jun 2023
Addition of venetoclax to lenalidomide and rituximab in patients with untreated MCL 2:00
Addition of venetoclax to lenalidomide and rituximab in patients with untreated MCL
Tycel Phillips • 2 Jun 2023
The role of venetoclax in R/R MCL & options for patients who progress on venetoclax 2:06
The role of venetoclax in R/R MCL & options for patients who progress on venetoclax
Tycel Phillips • 2 Jun 2023
Update on Phase I/II study of glofitamab monotherapy in R/R MCL 2:18
Update on Phase I/II study of glofitamab monotherapy in R/R MCL
Tycel Phillips • 5 Dec 2022
Phase I study of plamotamab in R/R NHL 1:24
Phase I study of plamotamab in R/R NHL
Tycel Phillips • 5 Dec 2022
The content of VJHemOnc is intended for healthcare professionals